A detailed history of Marshall Wace, LLP transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 2,333,117 shares of SWTX stock, worth $75.3 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
2,333,117
Previous 2,966,622 21.35%
Holding current value
$75.3 Million
Previous $146 Million 39.81%
% of portfolio
0.12%
Previous 0.23%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$36.06 - $47.62 $22.8 Million - $30.2 Million
-633,505 Reduced 21.35%
2,333,117 $87.9 Million
Q1 2024

May 15, 2024

SELL
$36.5 - $52.5 $2.13 Million - $3.06 Million
-58,237 Reduced 1.93%
2,966,622 $146 Million
Q4 2023

Feb 14, 2024

BUY
$18.94 - $37.24 $32.9 Million - $64.7 Million
1,736,606 Added 134.8%
3,024,859 $110 Million
Q3 2023

Nov 14, 2023

BUY
$23.12 - $31.38 $1.86 Million - $2.53 Million
80,613 Added 6.68%
1,288,253 $29.8 Million
Q2 2023

Aug 14, 2023

BUY
$23.15 - $32.71 $23.7 Million - $33.5 Million
1,023,306 Added 555.14%
1,207,640 $31.7 Million
Q1 2023

May 15, 2023

BUY
$24.97 - $34.05 $4.6 Million - $6.28 Million
184,334 New
184,334 $4.74 Million
Q2 2022

Aug 15, 2022

SELL
$18.36 - $60.07 $12.9 Million - $42.3 Million
-704,597 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$48.97 - $65.46 $14.5 Million - $19.4 Million
297,078 Added 72.9%
704,597 $39.8 Million
Q4 2021

Feb 14, 2022

BUY
$53.3 - $75.84 $20.6 Million - $29.3 Million
386,626 Added 1850.5%
407,519 $25.3 Million
Q3 2021

Nov 15, 2021

BUY
$62.66 - $88.26 $1.31 Million - $1.84 Million
20,893 New
20,893 $1.33 Million
Q2 2021

Aug 13, 2021

SELL
$67.45 - $85.63 $4.39 Million - $5.57 Million
-65,044 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$65.1 - $93.59 $4.23 Million - $6.09 Million
65,044 New
65,044 $4.79 Million

Others Institutions Holding SWTX

About SpringWorks Therapeutics, Inc.


  • Ticker SWTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,401,100
  • Market Cap $2.01B
  • Description
  • SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...
More about SWTX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.